

# Trial of aciclovir in the prophylaxis of herpes infections in critical care

<b>Submission date</b> 13/02/2006	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 14/03/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 19/05/2022	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Alexander Binning

**Contact details**  
Intensive Therapy Unit  
Western Infirmary  
Glasgow  
United Kingdom  
G11 5JR

## Additional identifiers

**EudraCT/CTIS number**  
2006-000612-24

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
WN06AN002

## Study information

**Scientific Title**

Trial of aciclovir in the prophylaxis of herpes infections in critical care

**Acronym**

TRAPHICC

**Study objectives**

The overall aim of this proof of concept study is to serve as a pilot study for a multicentre study powered to detect improvement in Intensive Care Unit (ICU) mortality by giving aciclovir prophylaxis to prevent Herpes Simplex Virus (HSV) infection in the lungs.

As of 01/06/2009 this record has been updated to include an extension to the anticipated end date; the initial end date at the time of registration was 31/05/2008.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Multi-Centre Research Ethics Committee for Scotland (Committee A) approved on the 28/03/2008 (ref: 06/MRE00/14; Protocol Number: 3; EudraCT Number: 2006-000612-24).

**Study design**

Double-blind, randomised, parallel group placebo-controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Prevention

**Participant information sheet****Health condition(s) or problem(s) studied**

Herpes simplex virus infection of the lower respiratory tract in critically ill patients

**Interventions**

Administration of 15 mg/kg per day aciclovir or placebo by infusion three times daily over 1 hour

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Aciclovir

**Primary outcome measure**

The primary endpoint is the mean change in Karnofsky index from baseline to day 28 +/- 2 days and 90 +/- 2 days after entry to the study

**Secondary outcome measures**

1. Proportion of patients with HSV detected during ICU stay in lower respiratory secretions; proportion of patients with HSV detected during ICU stay in blood samples
2. In patients in whom HSV is detected during ICU stay, proportions of infections due to primary infection and reactivation of latent infection
3. At each sampling time point, the correlation between HSV lymphocyte response and viral titres
4. Mean plasma soluble cytokine levels in patients with and without HSV infection; mean respiratory secretion soluble cytokine levels in patients with and without HSV infection
5. Proportions of patients with HSV reactivation according to type of cytokine response
6. Mean complement activation before HSV is detected, after HSV detection and in patients where HSV is not detected during ICU stay
7. Proportion of patients in whom each of Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Human Herpes Virus Six (HHV6) and Human Herpes Virus Seven (HHV7) infections are detected during ICU stay
8. Median number of days on ventilation, median ICU stay, frequency of prescription of each of anti-retroviral agents, corticosteroids, immunosuppressive agents
9. Proportion of patients surviving at 90 days following ICU admission
10. Number of days of survival following ICU admission
11. The survival time for patients surviving beyond 90 days will be censored at 90 days
12. Proportion of HSV infections which are HSV1, proportion of HSV infections which are HSV2
13. Mean vital signs, white cell count and creatinine clearance during ICU stay
14. Reporting of adverse events occurring during randomised treatment or during the 7 days following the end of randomised treatment

**Overall study start date**

01/06/2006

**Completion date**

30/09/2009

**Eligibility****Key inclusion criteria**

1. All patients 18 years or over entering ICU
2. Patient expected to stay in the ICU longer than 36 hours and intubated with an endotracheal or tracheostomy tube within 24 hours of admission to ICU
3. Patient not requiring treatment with aciclovir, valaciclovir, ganciclovir, foscarnet, probenecid or other drug known to have anti-herpes simplex activity
4. Patient must have no known allergy to aciclovir
5. Females of childbearing age must have negative pregnancy test on admission
6. Written informed consent from the patient or assent obtained from relatives

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

500

**Key exclusion criteria**

1. Duration of admission confidently expected to be less than 36 hours
2. Patients with endotracheal or tracheostomy tube placed more than 24 hours before admission to ICU
3. Patient has clinical features of HSV disease
4. Patient previously randomised to this study
5. Patients deemed to be suitable for entry to another trial
6. Previous hypersensitivity to aciclovir or valaciclovir
7. Patient requiring agent with anti-herpes virus activity
8. Patient previously enrolled in another trial of an investigational drug within the past 30 days
9. Patient is pregnant or lactating

**Date of first enrolment**

01/06/2006

**Date of final enrolment**

30/09/2009

**Locations**

**Countries of recruitment**

Scotland

United Kingdom

**Study participating centre**

**Intensive Therapy Unit**

Glasgow

United Kingdom

G11 5JR

**Sponsor information**

## Organisation

Greater Glasgow Health Board (North Glasgow University Hospitals Division) (UK)

## Sponsor details

Room 9  
Administration Building  
Western Infirmary  
Glasgow  
Scotland  
United Kingdom  
G11 6NT  
+44 (0)141 211 1817  
judith.godden@northglasgow.scot.nhs.uk

## Sponsor type

Hospital/treatment centre

## ROR

<https://ror.org/05kdz4d87>

## Funder(s)

### Funder type

Government

### Funder Name

Chief Scientist Office of the Scottish Executive Health Department (UK) (ref: CZB/4/375)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

Not provided at time of registration

### IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>		04/02/2021	19/05/2022	No	No